Stock Market Reviews

EDIT (Editas Medicine, Inc.) News

Get the latest news, insights, and market updates on EDIT (Editas Medicine, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
  Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 10, 2025 - $EDIT
• Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
  BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
  Nov 25, 2025 - $EDIT
• COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
  Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
  Nov 20, 2025 - $EDIT
• Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies
  TEL AVIV, Israel, November 20, 2025--Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies.
  Nov 20, 2025 - $EDIT
• Top 3 Genomics Stocks to Consider for Your Portfolio
  Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
  Nov 18, 2025 - $EDIT
• Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates
  Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its quarterly report and things are looking bullish. Revenues of...
  Nov 13, 2025 - $EDIT
• Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
  EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
  Nov 11, 2025 - $EDIT
• Editas: Q3 Earnings Snapshot
  CAMBRIDGE, Mass. AP) — Editas Medicine Inc. EDIT) on Monday reported a loss of $25.1 million in its third quarter.
  Nov 10, 2025 - $EDIT
• Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
  Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $EDIT
• Editas Medicine Announces Third Quarter 2025 Results and Business Updates
  In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027, enabling progression of EDIT-401 beyond initial human proof-of-concept data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- E
  Nov 10, 2025 - $EDIT